Topical Mitomycin C for the Treatment of Conjunctival and Corneal Epithelial Dysplasia and Neoplasia
References (29)
- et al.
Conjunctival and corneal intraepithelial and invasive neoplasia
Ophthalmology
(1986) - et al.
Clinical and pathological description of 17 cases of corneal intraepithelial neoplasia
Am J Ophthalmol
(1984) - et al.
Management of intraepithelial conjunctival tumors and squamous cell carcinomas
Am J Ophthalmol
(1983) - et al.
The use of strontium-90 in the treatment of carcinoma in situ of the conjunctiva
Am J Ophthalmol
(1979) - et al.
Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea
Ophthalmology
(1995) - et al.
Mitomycin C therapy for corneal intraepithelial neoplasia
Am J Ophthalmol
(1994) - et al.
Inhibition of corneal epithelial wound healing: a comparative study of mitomycin C and 5-fluorouracil
Ophthalmology
(1992) - et al.
Effects of 5-fluorouracil and mitomycin C on cultured rabbit subconjunctival fibroblasts
Ophthalmology
(1990) - et al.
Mitomycin eye drops as treatment for pterygium
Ophthalmology
(1988) Mitomycin as adjunct chemotherapy with trabeculectomy
Ophthalmology
(1991)
Serious complications of topical mitomycin C after pterygium surgery
Ophthalmology
Risk factors in the development of ocular surface epithelial dysplasia
Ophthalmology
Bowen's disease of the conjunctiva: a misnomer
Therapy of intraepithelial epitheliomas and squamous cell carcinoma of the limbus
Trans Am Ophthalmol Soc
Cited by (151)
Ocular surface complications of local anticancer drugs for treatment of ocular tumors
2021, Ocular SurfaceCitation Excerpt :One study by Russell et al. reported that long-term complications following topical MMC therapy occurred in 33% of cases [24]. The most common side effects are ocular irritation (30–100%) [15,18,19,22,23,25], allergic lid or conjunctival reaction (9.3–60%) [19–21,25–27], conjunctival hyperemia (8–100%) [15,19,21–23,28] and corneal epithelial erosions (1–50%) [15,19–23]. The most severe complication is cytotoxicity to limbal stem cells and corneal epithelial cells, leading to LSCD (0–12%) [15,18,24,26,29].
Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia
2019, American Journal of OphthalmologyTopical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia Presented Cornea Society/Fall Educational Symposium, November 2015, Las Vegas, Nevada.
2016, OphthalmologyCitation Excerpt :In our study, representing the largest group of patients treated with 5-FU as primary therapy to date, we found that 82% of patients experienced complete resolution of OSSN. Our response frequency of 82% for 5-FU is similar to what has been reported in larger series of IFN- and MMC-treated patients.11,20–26,28–35 One issue in comparing treatment response between 5-FU studies is that varying regimens have been used to treat OSSN.
The corneal fibrosis response to epithelial-Stromal injury
2016, Experimental Eye Research
No reprints are available.